IKNA vs. OCGN, AMRN, AARD, MDWD, TVGN, ANNX, FHTX, SLRN, DSGN, and URGN
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Ocugen (OCGN), Amarin (AMRN), Aardvark Therapeutics (AARD), MediWound (MDWD), Tevogen Bio (TVGN), Annexon (ANNX), Foghorn Therapeutics (FHTX), Acelyrin (SLRN), Design Therapeutics (DSGN), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.
Ikena Oncology vs. Its Competitors
Ikena Oncology (NASDAQ:IKNA) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
In the previous week, Ocugen had 2 more articles in the media than Ikena Oncology. MarketBeat recorded 4 mentions for Ocugen and 2 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.87 beat Ocugen's score of 0.65 indicating that Ikena Oncology is being referred to more favorably in the media.
Ikena Oncology has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500.
Ocugen received 85 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 71.43% of users gave Ocugen an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote.
75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Ocugen has higher revenue and earnings than Ikena Oncology. Ocugen is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.
Ikena Oncology has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Ikena Oncology's return on equity of -36.88% beat Ocugen's return on equity.
Ikena Oncology presently has a consensus price target of $3.00, suggesting a potential upside of 114.29%. Ocugen has a consensus price target of $6.00, suggesting a potential upside of 417.24%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Ikena Oncology.
Summary
Ocugen beats Ikena Oncology on 10 of the 18 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IKNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ikena Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:IKNA) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy IKNA Stock Free IKNA Stock Alerts